PMID- 22127697
OWN - NLM
STAT- MEDLINE
DCOM- 20120127
LR  - 20220408
IS  - 1529-0131 (Electronic)
IS  - 0004-3591 (Linking)
VI  - 63
IP  - 12
DP  - 2011 Dec
TI  - Radiographic progression is associated with resolution of systemic inflammation 
      in patients with axial spondylarthritis treated with tumor necrosis factor alpha 
      inhibitors: a study of radiographic progression, inflammation on magnetic 
      resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and 
      cartilage and bone turnover.
PG  - 3789-800
LID - 10.1002/art.30627 [doi]
AB  - OBJECTIVE: To investigate the relationship of circulating biomarkers of 
      inflammation (C-reactive protein [CRP], interleukin-6 [IL-6], and YKL-40), 
      angiogenesis (vascular endothelial growth factor), cartilage turnover (C-terminal 
      crosslinking telopeptide of type II collagen [CTX-II], total aggrecan, matrix 
      metalloproteinase 3 [MMP-3], and cartilage oligomeric matrix protein [COMP]), and 
      bone turnover (CTX-I and osteocalcin) to inflammation on magnetic resonance 
      imaging (MRI) and radiographic progression in patients with axial 
      spondylarthritis (SpA) beginning tumor necrosis factor alpha (TNFalpha) inhibitor 
      therapy. METHODS: MRIs were evaluated according to the Berlin sacroiliac (SI) 
      joint and spine inflammation scoring method at baseline, week 22, and week 46. 
      Radiographs were evaluated using the modified Stoke Ankylosing Spondylitis Spine 
      Score at baseline and week 46. Patients with new syndesmophytes were identified. 
      Biomarker levels in patients were compared to levels in healthy subjects. 
      RESULTS: Higher pretreatment MRI inflammation scores for SI joints and/or lumbar 
      spine were associated with higher baseline CTX-II levels, but not with higher 
      levels of biomarkers of inflammation and bone turnover. During treatment with 
      TNFalpha inhibitors, a decrease in MRI inflammation scores from baseline to week 22 
      was associated with larger percentage decreases in and a normalization of CRP and 
      IL-6 levels as compared to an increase or no change in MRI scores. Development of 
      new syndesmophytes was associated with larger percentage decreases in CRP and 
      IL-6 levels and an increase in osteocalcin level, and with normalization of CRP 
      and IL-6 levels from baseline to week 22. Persistent systemic inflammation was 
      associated with radiographic nonprogression. CONCLUSION: Our findings indicate 
      that inflammation on baseline MRI is associated with higher CTX-II levels. 
      Radiographic progression is associated with decreased systemic inflammation, as 
      assessed by IL-6 and CRP levels and MRI, supporting the notion of a link between 
      the resolution of inflammation and new bone formation in SpA patients during 
      anti-TNFalpha therapy.
CI  - Copyright (c) 2011 by the American College of Rheumatology.
FAU - Pedersen, Susanne Juhl
AU  - Pedersen SJ
AD  - Department of Rheumatology C Post 535, Gentofte University Hospital, Copenhagen, 
      Denmark. susanne_juhl_ped@dadlnet.dk
FAU - Sorensen, Inge Juul
AU  - Sorensen IJ
FAU - Lambert, Robert G W
AU  - Lambert RG
FAU - Hermann, Kay-Geert A
AU  - Hermann KG
FAU - Garnero, Patrick
AU  - Garnero P
FAU - Johansen, Julia Sidenius
AU  - Johansen JS
FAU - Madsen, Ole Rintek
AU  - Madsen OR
FAU - Hansen, Annette
AU  - Hansen A
FAU - Hansen, Michael Sejer
AU  - Hansen MS
FAU - Thamsborg, Gorm
AU  - Thamsborg G
FAU - Andersen, Lis Smedegaard
AU  - Andersen LS
FAU - Majgaard, Ole
AU  - Majgaard O
FAU - Loft, Anne Gitte
AU  - Loft AG
FAU - Erlendsson, Jon
AU  - Erlendsson J
FAU - Asmussen, Karsten H
AU  - Asmussen KH
FAU - Jurik, Anne Grethe
AU  - Jurik AG
FAU - Moller, Jakob
AU  - Moller J
FAU - Hasselquist, Maria
AU  - Hasselquist M
FAU - Mikkelsen, Dorrit
AU  - Mikkelsen D
FAU - Ostergaard, Mikkel
AU  - Ostergaard M
LA  - eng
SI  - ClinicalTrials.gov/NCT00133315
PT  - Journal Article
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers)
RN  - 0 (Cartilage Oligomeric Matrix Protein)
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Glycoproteins)
RN  - 0 (Interleukin-6)
RN  - 0 (Matrilin Proteins)
RN  - 0 (TSP5 protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 104982-03-8 (Osteocalcin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - B72HH48FLU (Infliximab)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Biomarkers/blood
MH  - Bone and Bones/*metabolism
MH  - C-Reactive Protein/metabolism
MH  - Cartilage/*metabolism
MH  - Cartilage Oligomeric Matrix Protein
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - *Disease Progression
MH  - Extracellular Matrix Proteins/blood
MH  - Female
MH  - Glycoproteins/blood
MH  - Humans
MH  - Inflammation/*diagnostic imaging/*pathology
MH  - Infliximab
MH  - Interleukin-6/blood
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Matrilin Proteins
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Neovascularization, Pathologic/*blood
MH  - Osteocalcin/blood
MH  - Prospective Studies
MH  - Radiography
MH  - Spondylarthritis/blood/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Vascular Endothelial Growth Factor A/blood
EDAT- 2011/12/01 06:00
MHDA- 2012/01/28 06:00
CRDT- 2011/12/01 06:00
PHST- 2011/12/01 06:00 [entrez]
PHST- 2011/12/01 06:00 [pubmed]
PHST- 2012/01/28 06:00 [medline]
AID - 10.1002/art.30627 [doi]
PST - ppublish
SO  - Arthritis Rheum. 2011 Dec;63(12):3789-800. doi: 10.1002/art.30627.